153 related articles for article (PubMed ID: 17477222)
1. High-dose methotrexate and primary central nervous system lymphoma.
Fahey JB; DiMaggio C
J Neurosci Nurs; 2007 Apr; 39(2):83-8. PubMed ID: 17477222
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
3. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
[TBL] [Abstract][Full Text] [Related]
4. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.
Joerger M; Huitema AD; Illerhaus G; Ferreri AJ
Leuk Lymphoma; 2012 Oct; 53(10):1867-75. PubMed ID: 22530664
[TBL] [Abstract][Full Text] [Related]
5. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
6. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients.
Guha-Thakurta N; Damek D; Pollack C; Hochberg FH
J Neurooncol; 1999 Jul; 43(3):259-68. PubMed ID: 10563432
[TBL] [Abstract][Full Text] [Related]
7. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
[TBL] [Abstract][Full Text] [Related]
10. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
11. Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate.
Warnick E; Auger D
Clin J Oncol Nurs; 2009 Apr; 13(2):177-80. PubMed ID: 19349264
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
Han X; Ji Y; Ouyang M; Zhu T; Zhou D
Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
Ferreri AJ; Reni M; Villa E
Ann Oncol; 2000 Aug; 11(8):927-37. PubMed ID: 11038028
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
16. Primary central nervous system lymphoma.
Mohile NA; Abrey LE
Semin Radiat Oncol; 2007 Jul; 17(3):223-9. PubMed ID: 17591569
[TBL] [Abstract][Full Text] [Related]
17. Flows and flaws in primary central nervous system lymphoma.
Ferreri AJ; Illerhaus G; Zucca E; Cavalli F;
Nat Rev Clin Oncol; 2010 Aug; 7(8):doi:10.1038/nrclinonc.2010.9-c1; author reply doi:10:1038/nrclinonc.2010.9-c2. PubMed ID: 20700952
[No Abstract] [Full Text] [Related]
18. Primary central nervous system lymphoma with testicular relapse.
Harney J; Pope A; Short SC
Clin Oncol (R Coll Radiol); 2004 May; 16(3):193-5. PubMed ID: 15191006
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.
Kiewe P; Loddenkemper C; Anagnostopoulos I; Reinwald M; Thiel E; Korfel A
Neuro Oncol; 2007 Apr; 9(2):96-102. PubMed ID: 17301290
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children.
Taj MM; Messahel B; Mycroft J; Pritchard-Jones K; Baker A; Height S; Hadzic N; Pinkerton CR
Br J Haematol; 2008 Jan; 140(2):191-6. PubMed ID: 18173755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
